Serum Peptide Profiling using MALDI Mass Spectrometry
暂无分享,去创建一个
Rainer Cramer | Celia J. Smith | Usha Menon | Musarat Kabir | Stephane Camuzeaux | John Timms | Ian Jacobs | I. Jacobs | U. Menon | M. Waterfield | S. Gayther | J. Timms | R. Cramer | A. Tiss | Ali Tiss | Celia Smith | Simon Gayther | Mike Waterfield | S. Camuzeaux | M. Kabir
[1] A. Yocum,et al. Effect of immunoaffinity depletion of human serum during proteomic investigations. , 2005, Journal of proteome research.
[2] D. S. Hage,et al. Obtaining high sequence coverage in matrix-assisted laser desorption time-of-flight mass spectrometry for studies of protein modification: analysis of human serum albumin as a model. , 2006, Analytical biochemistry.
[3] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[4] André M Deelder,et al. Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. , 2005, Analytical chemistry.
[5] E. Diamandis. Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.
[6] P. Tempst,et al. Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age*S , 2006, Molecular & Cellular Proteomics.
[7] T. Yip,et al. New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .
[8] Jeffrey R. Whiteaker,et al. Head-to-head comparison of serum fractionation techniques. , 2007, Journal of proteome research.
[9] T. M. Thomas,et al. Depletion of the highly abundant protein albumin from human plasma using the Gradiflow , 2003, Proteomics.
[10] K Chapman,et al. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. , 2001, Biochemical Society transactions.
[11] R. Tollenaar,et al. MALDI-TOF Serum Protein Profiling for the Detection of Breast Cancer , 2006, Oncology Research and Treatment.
[12] Thomas P Conrads,et al. SELDI-TOF MS for diagnostic proteomics. , 2003, Analytical chemistry.
[13] S. Weinberger,et al. Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.
[14] Rency S Varghese,et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma , 2006, Proteomics.
[15] M. Guilhaus,et al. Two‐dimensional liquid chromatography/tandem mass spectrometry analysis of Gradiflow™ fractionated native human plasma , 2005, Proteomics.
[16] Pär Stattin,et al. Correspondence re: B-L. Adam et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614, 2002. , 2003, Cancer research.
[17] Jeffrey S. Morris,et al. Serum proteomics profiling—a young technology begins to mature , 2005, Nature Biotechnology.
[18] E. Holland,et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.
[19] Ronald J. Moore,et al. Toward a Human Blood Serum Proteome , 2002, Molecular & Cellular Proteomics.
[20] M. Gustafsson,et al. Integrated sample preparation and MALDI mass spectrometry on a microfluidic compact disk. , 2004, Analytical chemistry.
[21] Eugene A. Kapp,et al. Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.
[22] Wayne F. Patton,et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. , 2007, Clinical chemistry.
[23] Emanuel F Petricoin,et al. Serum proteomics in cancer diagnosis and management. , 2004, Annual review of medicine.
[24] P. Schellhammer,et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.
[25] K. Kozak,et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Hanash,et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study , 2006, Nature Biotechnology.
[27] P. Tempst,et al. Automated serum peptide profiling , 2006, Nature Protocols.
[28] Chun-Ta Liao,et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. , 2005, Clinical chemistry.
[29] Erika Check,et al. Proteomics and cancer: Running before we can walk? , 2004, Nature.
[30] S. Baumann,et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.
[31] Hong Wang,et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system , 2005, Proteomics.
[32] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[33] B. Davis,et al. LC-MS/MS Quantification of Zn-α2 Glycoprotein: A Potential Serum Biomarker for Prostate Cancer , 2007 .
[34] Douglas C Pearl,et al. Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.
[35] Tomas Bergman,et al. Identification of Endothelial Proteins by MALDI-MS Using a Compact Disc Microfluidic System , 2004, The protein journal.
[36] E. Diamandis. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.
[37] S. Weinberger,et al. Recent trends in protein biochip technology. , 2000, Pharmacogenomics.
[38] D. Speicher,et al. Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma , 2005, Proteomics.
[39] B. Ye,et al. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer , 2007, Expert review of proteomics.
[40] T. Ried,et al. Sequential proteome alterations during genesis and progression of colon cancer , 2004, Cellular and Molecular Life Sciences CMLS.
[41] E. Marchiori,et al. Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.
[42] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[43] Min-Seok Kwon,et al. Efficient prefractionation of low‐abundance proteins in human plasma and construction of a two‐dimensional map , 2005, Proteomics.
[44] P. Tempst,et al. Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.
[45] W. Barrett,et al. Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.
[46] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[47] Cornelis J H van de Velde,et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. , 2006, European journal of cancer.
[48] A. Sinaiko,et al. Plasma protein profiling: Unique and stable features of individuals , 2005, Proteomics.
[49] Ronald J Moore,et al. Characterization of the human blood plasma proteome , 2005, Proteomics.
[50] E. Petricoin,et al. Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.
[51] N. Heegaard,et al. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.